Sandoz Group（SDZ）株式概要サンドグループAGは、ジェネリック医薬品およびバイオシミラーの開発、製造、販売を世界中で行っている。 詳細SDZ ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績2/6財務の健全性6/6配当金2/6報酬当社が推定した公正価値より35.7%で取引されている 収益は年間16.94%増加すると予測されています リスク分析リスクチェックの結果、SDZ 、リスクは検出されなかった。すべてのリスクチェックを見るSDZ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,172 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,172 investors already sharing narrativesYour Fair Value€Current Price€70.703.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture014b2016201920222025202620282031Revenue US$14.3bEarnings US$1.2bAdvancedSet Fair ValueView all narrativesSandoz Group AG 競合他社Teva Pharmaceutical IndustriesSymbol: NYSE:TEVAMarket cap: US$37.5bOtsuka HoldingsSymbol: TSE:4578Market cap: JP¥5.8tZoetisSymbol: NYSE:ZTSMarket cap: US$32.2bRoyalty PharmaSymbol: NasdaqGS:RPRXMarket cap: US$33.7b価格と性能株価の高値、安値、推移の概要Sandoz Group過去の株価現在の株価CHF 70.7052週高値CHF 80.8252週安値CHF 52.52ベータ0.501ヶ月の変化-5.46%3ヶ月変化-1.06%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化32.79%最新ニュースお知らせ • 20hSandoz Group AG Announces Management ChangesSandoz Group AG announced several key leadership changes. Pascal Bouye was appointed President, Generics Manufacturing & Supply, and a member of the Sandoz Executive Committee (SEC), effective August 20, 2026. He succeeded Glenn Gerecke, who stepped down from the SEC and took on a new role within the company. Pascal Bouye is a seasoned executive with over 30 years of experience building and transforming world-class global supply chains in highly regulated parts of the fast-moving consumer goods industry. He previously held senior roles in Danone and Mars, where he led global teams through complex operational transformations and drove continuous improvement. Keren Haruvi, President, North America, assumed overall responsibility for global M&A activities at Sandoz, in addition to her current role, effective August 1, 2026. Before joining Sandoz, she served as Global Head of M&A at Novartis, leading major strategic transactions and portfolio-shaping initiatives. Simon Goeller, currently Global Head, Transformation & Growth (T&G) and a member of the Extended Leadership Team, was appointed Country President, Germany, the second largest Sandoz market worldwide, effective August 1, 2026. Thomas Weigold, currently Country President, Germany, assumed a new role as Head, Central Cluster, Europe, effective August 1, 2026. Max Juerging, currently Global Head Transformation, Integration & Separation, led the T&G team on an ad interim basis during recruitment for Mr. Goeller’s successor, effective August 1, 2026.お知らせ • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.最新情報をもっと見るRecent updatesお知らせ • 20hSandoz Group AG Announces Management ChangesSandoz Group AG announced several key leadership changes. Pascal Bouye was appointed President, Generics Manufacturing & Supply, and a member of the Sandoz Executive Committee (SEC), effective August 20, 2026. He succeeded Glenn Gerecke, who stepped down from the SEC and took on a new role within the company. Pascal Bouye is a seasoned executive with over 30 years of experience building and transforming world-class global supply chains in highly regulated parts of the fast-moving consumer goods industry. He previously held senior roles in Danone and Mars, where he led global teams through complex operational transformations and drove continuous improvement. Keren Haruvi, President, North America, assumed overall responsibility for global M&A activities at Sandoz, in addition to her current role, effective August 1, 2026. Before joining Sandoz, she served as Global Head of M&A at Novartis, leading major strategic transactions and portfolio-shaping initiatives. Simon Goeller, currently Global Head, Transformation & Growth (T&G) and a member of the Extended Leadership Team, was appointed Country President, Germany, the second largest Sandoz market worldwide, effective August 1, 2026. Thomas Weigold, currently Country President, Germany, assumed a new role as Head, Central Cluster, Europe, effective August 1, 2026. Max Juerging, currently Global Head Transformation, Integration & Separation, led the T&G team on an ad interim basis during recruitment for Mr. Goeller’s successor, effective August 1, 2026.お知らせ • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 28Full year 2025 earnings releasedFull year 2025 results: EPS: US$2.12. Revenue: US$11.2b (up 7.4% from FY 2024). Net income: US$914.0m (up US$914.0m from FY 2024). Profit margin: 8.2% (up from 0% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe.お知らせ • Feb 27Sandoz Group AG announces Annual dividend, payable on April 15, 2026Sandoz Group AG announced Annual dividend of CHF 0.8000 per share payable on April 15, 2026, ex-date on April 13, 2026 and record date on April 14, 2026.お知らせ • Feb 26Sandoz Confirms European Commission Approval for Ranluspec®? (Ranibizumab)Sandoz confirmed that the European Commission has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®?. Around four million people are estimated to have neovascular age-related macular degenerization in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. The announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope®? (somatropin), in 2006. It strengthens the company's position in ophthalmology, following the launch of Afqlir®? (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy®? (ranibizumab) in Germany under a separate agreement. Lucentis®? is a registered trademark of Genentech Inc.お知らせ • Feb 21Sandoz Group AG Receives US FDA Approval to Expand Enzeevu (Aflibercept-Abzv) Label for Multiple Retinal IndicationsSandoz Group AG on February 18, 2026 announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 2024. The most recent approval expands the Enzeevu label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) in 2024 and the European launch of Afqlir (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected approx. USD 320 billion biosimilar market opportunity over the next 10 years . Enzeevu is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances.Board Change • Feb 05High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 16Sandoz Confirms European Commission Approval of Ondibta® (Insulin Glargine)Sandoz confirmed that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for injection in a pre-filled pen developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above and is confirmed to match the reference medicine, Lantus® SoloStar® insulin pen, in terms of safety, quality and efficacy. The approval paves the way for an expected launch of Ondibta® by early 2027, which has the potential to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin that it produces. It can cause blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to latest estimates, there are 66 million adults aged 20-79 living with diabetes in Europe, a figure that is expected to increase 10% by 2050 to 72 million, with related healthcare expenditure approaching USD 200 billion. Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialize biosimilar versions of the insulins glargine, lispro and aspart. Under the terms of the agreement, Sandoz will commercialize in Europe and other key territories around the world, while Gan & Lee is responsible for development, registration, manufacturing and supply. The approval builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It also strengthens the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development.Board Change • Jan 07High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 15High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 03Sandoz Launches Denosumab Biosimilars in Europe, Providing Affordable Treatment Option for Cancer-Related Bone Disease and Osteoporosis for Millions of PatientsSandoz announced the European launch of Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva ® (denosumab 120 mg) and Prolia (denosumab 60 mg). Wyost ® is approved for the treatment of cancer-related bone disease and Jubbonti ® is approved to treat osteoporosis. Wyost ® and Jubbonti ® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost ® and Jubbonti ® in the US and the recent launches of Tyruko ® (natalizumab) in the US and Afqlir ® (aflibercept) in Europe. Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate Wyost ® and Jubbonti ® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion and reinforces its established position in oncology and immunology. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Wyost ® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Jubbonti ® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.お知らせ • Nov 25Sandoz Group AG Launches Afqlir®? (aflibercept) in Europe, Providing Affordable Treatment Option for Patients with Retinal DiseasesSandoz Group AG announced the European launch of Afqlir ® (aflibercept). Afqlir ®, a 2 mg vial kit and pre-filled syringe for intravitreal injection, was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea ®, namely the treatment of various retinal diseases to prevent disease-related blindness. Studies confirm that Afqlir ® matches the reference medicine in efficacy, safety and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases. Conditions like age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) are leading causes of vision loss and their global prevalence is increasing. A subtype of age-related macular degeneration (AMD), nAMD is characterized by vision loss in the central zone and is a leading cause of vision impairment in patients over 65 years of age. Although nAMD represents about 10 to 20 percent of all AMD cases, it accounts for 90 percent of severe vision loss linked to AMD. In France, Germany, Italy, Spain, the UK, the US and Japan, around 4.0 million people are estimated to have nAMD. Of these, 2.8 million are diagnosed but only 2.0 million receive treatment. Afqlir ® will be launched across Europe, beginning in the UK, followed by other major markets such as Germany and France, with additional rollouts to follow in 2026. Afqlir ® is one of several biosimilar value drivers for Sandoz and this launch represents another step in advancing the company’s growth strategy, building on major launches this year including Tyruko ® (natalizumab) and Wyost ® (denosumab) and Jubbonti ® (denosumab) in the US. Sandoz is committed to helping million of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. The launch builds on the existing Sandoz leadership and legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006, and expands the company’s presence in the ~USD 15 billion anti-VEGF ophthalmology market. In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals Inc. to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026.お知らせ • Nov 16Sandoz Group AG to Report First Half, 2026 Results on Aug 05, 2026Sandoz Group AG announced that they will report first half, 2026 results on Aug 05, 2026Board Change • Oct 30High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.株主還元SDZAT PharmaceuticalsAT 市場7D-3.8%-0.2%-1.5%1Yn/a16.9%30.7%株主還元を見る業界別リターン: SDZがAustrian Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: SDZ Austrian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is SDZ's price volatile compared to industry and market?SDZ volatilitySDZ Average Weekly Movement3.5%Pharmaceuticals Industry Average Movement5.1%Market Average Movement4.2%10% most volatile stocks in AT Market6.3%10% least volatile stocks in AT Market2.5%安定した株価: SDZ 、 Austrian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SDZの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト188622,356Richard Saynorwww.sandoz.comサンドグループAGは、ジェネリック医薬品およびバイオシミラーの開発、製造、販売を世界中で行っている。同社は、循環器、中枢神経、腫瘍、感染症、疼痛・呼吸器、糖尿病、免疫、内分泌、血液、眼科などの治療領域をカバーしている。また、原薬や最終製剤のポートフォリオも提供している。同社は1886年に設立され、スイスのバーゼルに本社を置いている。もっと見るSandoz Group AG 基礎のまとめSandoz Group の収益と売上を時価総額と比較するとどうか。SDZ 基礎統計学時価総額€30.80b収益（TTM）€799.02m売上高(TTM)€9.75b38.6xPER（株価収益率3.2xP/SレシオSDZ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SDZ 損益計算書（TTM）収益US$11.16b売上原価US$5.86b売上総利益US$5.30bその他の費用US$4.39b収益US$914.00m直近の収益報告Dec 31, 2025次回決算日Aug 05, 2026一株当たり利益（EPS）2.11グロス・マージン47.50%純利益率8.19%有利子負債／自己資本比率56.6%SDZ の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.2%現在の配当利回り48%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 04:57終値2026/07/17 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sandoz Group AG 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。36 アナリスト機関Emily FieldBarclaysJames GordonBarclaysSidhartha ModiBarclays33 その他のアナリストを表示
お知らせ • 20hSandoz Group AG Announces Management ChangesSandoz Group AG announced several key leadership changes. Pascal Bouye was appointed President, Generics Manufacturing & Supply, and a member of the Sandoz Executive Committee (SEC), effective August 20, 2026. He succeeded Glenn Gerecke, who stepped down from the SEC and took on a new role within the company. Pascal Bouye is a seasoned executive with over 30 years of experience building and transforming world-class global supply chains in highly regulated parts of the fast-moving consumer goods industry. He previously held senior roles in Danone and Mars, where he led global teams through complex operational transformations and drove continuous improvement. Keren Haruvi, President, North America, assumed overall responsibility for global M&A activities at Sandoz, in addition to her current role, effective August 1, 2026. Before joining Sandoz, she served as Global Head of M&A at Novartis, leading major strategic transactions and portfolio-shaping initiatives. Simon Goeller, currently Global Head, Transformation & Growth (T&G) and a member of the Extended Leadership Team, was appointed Country President, Germany, the second largest Sandoz market worldwide, effective August 1, 2026. Thomas Weigold, currently Country President, Germany, assumed a new role as Head, Central Cluster, Europe, effective August 1, 2026. Max Juerging, currently Global Head Transformation, Integration & Separation, led the T&G team on an ad interim basis during recruitment for Mr. Goeller’s successor, effective August 1, 2026.
お知らせ • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.
Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .
Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.
お知らせ • 20hSandoz Group AG Announces Management ChangesSandoz Group AG announced several key leadership changes. Pascal Bouye was appointed President, Generics Manufacturing & Supply, and a member of the Sandoz Executive Committee (SEC), effective August 20, 2026. He succeeded Glenn Gerecke, who stepped down from the SEC and took on a new role within the company. Pascal Bouye is a seasoned executive with over 30 years of experience building and transforming world-class global supply chains in highly regulated parts of the fast-moving consumer goods industry. He previously held senior roles in Danone and Mars, where he led global teams through complex operational transformations and drove continuous improvement. Keren Haruvi, President, North America, assumed overall responsibility for global M&A activities at Sandoz, in addition to her current role, effective August 1, 2026. Before joining Sandoz, she served as Global Head of M&A at Novartis, leading major strategic transactions and portfolio-shaping initiatives. Simon Goeller, currently Global Head, Transformation & Growth (T&G) and a member of the Extended Leadership Team, was appointed Country President, Germany, the second largest Sandoz market worldwide, effective August 1, 2026. Thomas Weigold, currently Country President, Germany, assumed a new role as Head, Central Cluster, Europe, effective August 1, 2026. Max Juerging, currently Global Head Transformation, Integration & Separation, led the T&G team on an ad interim basis during recruitment for Mr. Goeller’s successor, effective August 1, 2026.
お知らせ • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.
Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .
Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 28Full year 2025 earnings releasedFull year 2025 results: EPS: US$2.12. Revenue: US$11.2b (up 7.4% from FY 2024). Net income: US$914.0m (up US$914.0m from FY 2024). Profit margin: 8.2% (up from 0% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe.
お知らせ • Feb 27Sandoz Group AG announces Annual dividend, payable on April 15, 2026Sandoz Group AG announced Annual dividend of CHF 0.8000 per share payable on April 15, 2026, ex-date on April 13, 2026 and record date on April 14, 2026.
お知らせ • Feb 26Sandoz Confirms European Commission Approval for Ranluspec®? (Ranibizumab)Sandoz confirmed that the European Commission has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®?. Around four million people are estimated to have neovascular age-related macular degenerization in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. The announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope®? (somatropin), in 2006. It strengthens the company's position in ophthalmology, following the launch of Afqlir®? (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy®? (ranibizumab) in Germany under a separate agreement. Lucentis®? is a registered trademark of Genentech Inc.
お知らせ • Feb 21Sandoz Group AG Receives US FDA Approval to Expand Enzeevu (Aflibercept-Abzv) Label for Multiple Retinal IndicationsSandoz Group AG on February 18, 2026 announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 2024. The most recent approval expands the Enzeevu label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) in 2024 and the European launch of Afqlir (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected approx. USD 320 billion biosimilar market opportunity over the next 10 years . Enzeevu is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances.
Board Change • Feb 05High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 16Sandoz Confirms European Commission Approval of Ondibta® (Insulin Glargine)Sandoz confirmed that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for injection in a pre-filled pen developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above and is confirmed to match the reference medicine, Lantus® SoloStar® insulin pen, in terms of safety, quality and efficacy. The approval paves the way for an expected launch of Ondibta® by early 2027, which has the potential to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin that it produces. It can cause blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to latest estimates, there are 66 million adults aged 20-79 living with diabetes in Europe, a figure that is expected to increase 10% by 2050 to 72 million, with related healthcare expenditure approaching USD 200 billion. Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialize biosimilar versions of the insulins glargine, lispro and aspart. Under the terms of the agreement, Sandoz will commercialize in Europe and other key territories around the world, while Gan & Lee is responsible for development, registration, manufacturing and supply. The approval builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It also strengthens the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development.
Board Change • Jan 07High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 15High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 03Sandoz Launches Denosumab Biosimilars in Europe, Providing Affordable Treatment Option for Cancer-Related Bone Disease and Osteoporosis for Millions of PatientsSandoz announced the European launch of Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva ® (denosumab 120 mg) and Prolia (denosumab 60 mg). Wyost ® is approved for the treatment of cancer-related bone disease and Jubbonti ® is approved to treat osteoporosis. Wyost ® and Jubbonti ® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost ® and Jubbonti ® in the US and the recent launches of Tyruko ® (natalizumab) in the US and Afqlir ® (aflibercept) in Europe. Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate Wyost ® and Jubbonti ® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion and reinforces its established position in oncology and immunology. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Wyost ® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Jubbonti ® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
お知らせ • Nov 25Sandoz Group AG Launches Afqlir®? (aflibercept) in Europe, Providing Affordable Treatment Option for Patients with Retinal DiseasesSandoz Group AG announced the European launch of Afqlir ® (aflibercept). Afqlir ®, a 2 mg vial kit and pre-filled syringe for intravitreal injection, was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea ®, namely the treatment of various retinal diseases to prevent disease-related blindness. Studies confirm that Afqlir ® matches the reference medicine in efficacy, safety and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases. Conditions like age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) are leading causes of vision loss and their global prevalence is increasing. A subtype of age-related macular degeneration (AMD), nAMD is characterized by vision loss in the central zone and is a leading cause of vision impairment in patients over 65 years of age. Although nAMD represents about 10 to 20 percent of all AMD cases, it accounts for 90 percent of severe vision loss linked to AMD. In France, Germany, Italy, Spain, the UK, the US and Japan, around 4.0 million people are estimated to have nAMD. Of these, 2.8 million are diagnosed but only 2.0 million receive treatment. Afqlir ® will be launched across Europe, beginning in the UK, followed by other major markets such as Germany and France, with additional rollouts to follow in 2026. Afqlir ® is one of several biosimilar value drivers for Sandoz and this launch represents another step in advancing the company’s growth strategy, building on major launches this year including Tyruko ® (natalizumab) and Wyost ® (denosumab) and Jubbonti ® (denosumab) in the US. Sandoz is committed to helping million of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. The launch builds on the existing Sandoz leadership and legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006, and expands the company’s presence in the ~USD 15 billion anti-VEGF ophthalmology market. In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals Inc. to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026.
お知らせ • Nov 16Sandoz Group AG to Report First Half, 2026 Results on Aug 05, 2026Sandoz Group AG announced that they will report first half, 2026 results on Aug 05, 2026
Board Change • Oct 30High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
